Chinook Therapeutics, Inc.
KDNYNASDAQHealthcare
$40.39
+$0.09(+0.22%)
Market Cap$2.7B
P/E Ratio—
52W High$40.51
52W Low$18.34
Chinook Therapeutics, Inc. (KDNY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KDNY · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2023Report Date: Aug 7, 2023EPS Actual
-$0.94
Est. -$0.81 · -16.1%
Revenue
$0.00B
Est. $0.00B · +320.0%
Fiscal Period
Q3 FY2023
FY ends December
Report Date
Aug 7, 2023
After Market Close
▼ Miss EPS▲ Beat Revenue
KDNY reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Aug 5, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 7, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Feb 26, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2023 | Nov 9, 2023 | -$0.84 | — | — | — | — | — |
| ▼ Q3 FY2023 | Aug 7, 2023 | -$0.81 | -$0.94 | -16.1% | $0.00B | $0.00B | +320.0% |
| ▼ Q2 FY2023 | May 9, 2023 | -$0.80 | -$0.85 | -6.3% | $0.00B | $0.00B | +661.7% |
| ▼ Q1 FY2023 | Feb 27, 2023 | -$0.79 | -$0.90 | -13.9% | $0.00B | $0.00B | +412.0% |
| ▼ Q4 FY2022 | Nov 10, 2022 | -$0.62 | -$0.83 | -33.9% | $0.00B | — | — |
Q3 FY2024
Aug 5, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 7, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Feb 26, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 9, 2023
EPS Actual
—
EPS Est.
-$0.84
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 7, 2023Miss
EPS Actual
-$0.94
EPS Est.
-$0.81
EPS Surpr.
-16.1%
Revenue
$0.00B
Q2 FY2023
May 9, 2023Miss
EPS Actual
-$0.85
EPS Est.
-$0.80
EPS Surpr.
-6.3%
Revenue
$0.00B
Q1 FY2023
Feb 27, 2023Miss
EPS Actual
-$0.90
EPS Est.
-$0.79
EPS Surpr.
-13.9%
Revenue
$0.00B
Q4 FY2022
Nov 10, 2022Miss
EPS Actual
-$0.83
EPS Est.
-$0.62
EPS Surpr.
-33.9%
Revenue
$0.00B
No analyst estimates available for KDNY.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2023 | Aug 7, 2023 | -16.1% | $40.28 | $40.35 | +0.17% |
| ▼ Q2 FY2023 | May 9, 2023 | -6.3% | $21.11 | $21.52 | +1.94% |
| ▼ Q1 FY2023 | Feb 27, 2023 | -13.9% | $21.71 | $21.57 | -0.64% |
| ▼ Q4 FY2022 | Nov 10, 2022 | -33.9% | $21.95 | $22.46 | +2.32% |
| ▲ Q3 FY2022 | Aug 8, 2022 | +1.6% | $20.44 | $20.49 | +0.24% |
| ▲ Q2 FY2022 | May 12, 2022 | +20.6% | $13.27 | $13.11 | -1.21% |
| ▼ Q1 FY2022 | Mar 17, 2022 | -79.4% | $13.75 | $13.85 | +0.73% |
| ▲ Q4 FY2021 | Nov 8, 2021 | +17.1% | $15.96 | $14.19 | -11.09% |
Q3 FY2023+0.17%
Report Date
Aug 7, 2023
EPS Beat/Miss
-16.1%
Price Before
$40.28
Price After
$40.35
Q2 FY2023+1.94%
Report Date
May 9, 2023
EPS Beat/Miss
-6.3%
Price Before
$21.11
Price After
$21.52
Q1 FY2023-0.64%
Report Date
Feb 27, 2023
EPS Beat/Miss
-13.9%
Price Before
$21.71
Price After
$21.57
Q4 FY2022+2.32%
Report Date
Nov 10, 2022
EPS Beat/Miss
-33.9%
Price Before
$21.95
Price After
$22.46
Q3 FY2022+0.24%
Report Date
Aug 8, 2022
EPS Beat/Miss
+1.6%
Price Before
$20.44
Price After
$20.49
Q2 FY2022-1.21%
Report Date
May 12, 2022
EPS Beat/Miss
+20.6%
Price Before
$13.27
Price After
$13.11
Q1 FY2022+0.73%
Report Date
Mar 17, 2022
EPS Beat/Miss
-79.4%
Price Before
$13.75
Price After
$13.85
Q4 FY2021-11.09%
Report Date
Nov 8, 2021
EPS Beat/Miss
+17.1%
Price Before
$15.96
Price After
$14.19
Avg Beat Reaction-4.02%
Avg Miss Reaction+0.90%
Beat Rate3 / 8 quarters
Largest Move-11.09% (Q4 FY2021)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KDNY ends December
Chinook Therapeutics, Inc. (KDNY) most recently reported earnings on August 7, 2023 for Q3 FY2023, posting EPS of $-0.94 — missing the analyst consensus of $-0.81 by -16.1%. The next KDNY earnings date is expected around September 1, 2026.
Each quarter, investors track KDNY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KDNY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KDNY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KDNY earnings · 5 questionsChinook Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. KDNY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KDNY historically reports after market close (AMC).
KDNY earnings datewhen is KDNY earningsKDNY next earnings datewhen does KDNY report earningsKDNY earnings calendar
▸ Source: FMP · Chinook Therapeutics, Inc. SEC filings · US GAAP · Chinook Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026